Top segments and regional performance

Last year, the company generated ‪2.32 B‬ USD, the most of which — ‪2.32 B‬ USD — came from its top-performing segment, Medicines for Difficult-to-treat Cancers, compared to ‪2.17 B‬ USD the previous year. The greatest contribution came from United States, which accounted for ‪2.14 B‬ USD last year, with ‪1.82 B‬ USD the year before.